Jaguar Health (JAGX)
Market Price (1/22/2026): $0.8116 | Market Cap: $1.2 MilSector: Health Care | Industry: Biotechnology
Jaguar Health (JAGX)
Market Price (1/22/2026): $0.8116Market Cap: $1.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -48% | Weak multi-year price returns2Y Excs Rtn is -145%, 3Y Excs Rtn is -172% | Penny stockMkt Price is 0.8 |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Health & Wellness Trends. Themes include Biopharmaceutical R&D, and Organic & Natural Products. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -33 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -279% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 2315% | ||
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.8% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -221%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -223% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3291% | ||
| High stock price volatilityVol 12M is 2522% | ||
| Key risksJAGX key risks include [1] substantial "going concern" risk due to severe financial instability, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -48% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Health & Wellness Trends. Themes include Biopharmaceutical R&D, and Organic & Natural Products. |
| Weak multi-year price returns2Y Excs Rtn is -145%, 3Y Excs Rtn is -172% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18% |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -33 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -279% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 2315% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -0.8% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -221%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -223% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3291% |
| High stock price volatilityVol 12M is 2522% |
| Key risksJAGX key risks include [1] substantial "going concern" risk due to severe financial instability, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Jaguar Health (JAGX) stock has lost about 65% since 9/30/2025 because of the following key factors:
1. Persistent Operating Losses and Negative Cash Flow. Jaguar Health consistently reported net losses, indicating a fundamental lack of profitability. For the third quarter of 2025, the company reported a net loss of $9.5 million and a Non-GAAP recurring EBITDA net loss of $8.9 million. The trailing twelve-month diluted EPS was notably negative at -$34.74, coupled with a concerning cash burn rate. Operating cash outflow reached $4.68 million, with negative working capital of $6.72 million, highlighting significant short-term liquidity challenges. Profitability ratios, such as an EBIT margin of -382.2% and a negative return on equity of -511.57%, further underscore these financial difficulties.
2. Dilutive Financing Activities. The company continued to seek and secure additional financing through methods that resulted in equity dilution. In the third quarter of 2025, Jaguar Health raised $13.88 million via equity offerings and convertible notes. Prior to this, in June 2025, it extended the maturity of approximately $2.57 million in convertible promissory notes and announced a $1.5 million direct offering. More recently, in January 2026, the company issued $350,000 in unsecured promissory notes and granted warrants to purchase up to 350,000 shares of common stock, which introduced a potential future equity overhang.
Show more
1. Persistent Operating Losses and Negative Cash Flow. Jaguar Health consistently reported net losses, indicating a fundamental lack of profitability. For the third quarter of 2025, the company reported a net loss of $9.5 million and a Non-GAAP recurring EBITDA net loss of $8.9 million. The trailing twelve-month diluted EPS was notably negative at -$34.74, coupled with a concerning cash burn rate. Operating cash outflow reached $4.68 million, with negative working capital of $6.72 million, highlighting significant short-term liquidity challenges. Profitability ratios, such as an EBIT margin of -382.2% and a negative return on equity of -511.57%, further underscore these financial difficulties.
2. Dilutive Financing Activities. The company continued to seek and secure additional financing through methods that resulted in equity dilution. In the third quarter of 2025, Jaguar Health raised $13.88 million via equity offerings and convertible notes. Prior to this, in June 2025, it extended the maturity of approximately $2.57 million in convertible promissory notes and announced a $1.5 million direct offering. More recently, in January 2026, the company issued $350,000 in unsecured promissory notes and granted warrants to purchase up to 350,000 shares of common stock, which introduced a potential future equity overhang.
Show more
Stock Movement Drivers
Fundamental Drivers
The -58.3% change in JAGX stock from 10/31/2025 to 1/21/2026 was primarily driven by a -49.1% change in the company's Shares Outstanding (Mil).| 10312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.94 | 0.81 | -58.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 12 | 12 | -0.2% |
| P/S Multiple | 0.2 | 0.1 | -37.7% |
| Shares Outstanding (Mil) | 1 | 2 | -49.1% |
| Cumulative Contribution | -68.4% |
Market Drivers
10/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| JAGX | -58.3% | |
| Market (SPY) | 0.5% | 21.2% |
| Sector (XLV) | 9.7% | -3.1% |
Fundamental Drivers
The -60.3% change in JAGX stock from 7/31/2025 to 1/21/2026 was primarily driven by a -141.5% change in the company's Shares Outstanding (Mil).| 7312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.04 | 0.81 | -60.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 12 | 12 | 2.0% |
| P/S Multiple | 0.1 | 0.1 | -6.1% |
| Shares Outstanding (Mil) | 1 | 2 | -141.5% |
| Cumulative Contribution | -139.7% |
Market Drivers
7/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| JAGX | -60.3% | |
| Market (SPY) | 8.7% | 23.7% |
| Sector (XLV) | 21.9% | 3.0% |
Fundamental Drivers
The -96.3% change in JAGX stock from 1/31/2025 to 1/21/2026 was primarily driven by a -303.7% change in the company's Shares Outstanding (Mil).| 1312025 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 22.11 | 0.81 | -96.3% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 10 | 12 | 12.5% |
| P/S Multiple | 0.8 | 0.1 | -86.9% |
| Shares Outstanding (Mil) | 0 | 2 | -303.7% |
| Cumulative Contribution | -130.1% |
Market Drivers
1/31/2025 to 1/21/2026| Return | Correlation | |
|---|---|---|
| JAGX | -96.3% | |
| Market (SPY) | 14.9% | 10.2% |
| Sector (XLV) | 9.2% | 4.8% |
Fundamental Drivers
The -100.0% change in JAGX stock from 1/31/2023 to 1/21/2026 was primarily driven by a -125266.9% change in the company's Shares Outstanding (Mil).| 1312023 | 1212026 | Change | |
|---|---|---|---|
| Stock Price ($) | 6795.00 | 0.81 | -100.0% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 11 | 12 | 9.4% |
| P/S Multiple | 0.8 | 0.1 | -86.4% |
| Shares Outstanding (Mil) | 0 | 2 | -125266.9% |
| Cumulative Contribution | -18784.6% |
Market Drivers
1/31/2023 to 1/21/2026| Return | Correlation | |
|---|---|---|
| JAGX | -100.0% | |
| Market (SPY) | 74.9% | 8.1% |
| Sector (XLV) | 24.2% | 3.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| JAGX Return | -57% | -92% | -98% | -89% | -96% | -8% | -100% |
| Peers Return | -16% | -28% | -41% | -66% | -32% | 7% | -91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| JAGX Win Rate | 17% | 8% | 33% | 25% | 17% | 0% | |
| Peers Win Rate | 36% | 50% | 53% | 29% | 56% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 0% | |
Max Drawdowns [4] | |||||||
| JAGX Max Drawdown | -58% | -92% | -98% | -91% | -99% | -26% | |
| Peers Max Drawdown | -30% | -45% | -60% | -67% | -49% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ACSB, AKTS, ALPS, APRI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/21/2026 (YTD)
How Low Can It Go
| Event | JAGX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -100.0% | -25.4% |
| % Gain to Breakeven | 599900.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -80.2% | -33.9% |
| % Gain to Breakeven | 405.3% | 51.3% |
| Time to Breakeven | 36 days | 148 days |
| 2018 Correction | ||
| % Loss | -100.0% | -19.8% |
| % Gain to Breakeven | 248036.7% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to VRTX, ACSB, AKTS, ALPS, APRI
In The Past
Jaguar Health's stock fell -100.0% during the 2022 Inflation Shock from a high on 1/8/2021. A -100.0% loss requires a 599900.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
AI Analysis | Feedback
Here are 1-3 brief analogies for Jaguar Health (JAGX):
- Think of it as a Zoetis for gut health medicines, with a dual focus on both animal and human treatments.
- It's a small biotech focused on developing breakthrough treatments for digestive diseases, akin to an aspiring Vertex Pharmaceuticals for gut conditions.
- Imagine a smaller, pre-breakthrough Moderna, but dedicated to gastrointestinal therapies rather than mRNA vaccines.
AI Analysis | Feedback
- Mytesi (crofelemer): A prescription drug approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Canalevia-CA1 (crofelemer): A conditionally approved oral prescription drug for the treatment of chemotherapy-induced diarrhea in dogs.
AI Analysis | Feedback
Jaguar Health (JAGX) primarily sells its pharmaceutical products to other companies, specifically major pharmaceutical wholesale distributors. These distributors then supply the drugs to pharmacies, hospitals, and other healthcare providers who dispense them to patients. The major customers for Jaguar Health are likely to include the largest pharmaceutical wholesale distributors in the United States:- McKesson Corporation (NYSE: MCK)
- Cardinal Health, Inc. (NYSE: CAH)
- AmerisourceBergen Corporation (NYSE: ABC)
AI Analysis | Feedback
| Supplier Company Name | Symbol (if public) |
|---|---|
| C&C Biotech | |
| Glenmark Pharmaceuticals Ltd. | NSE: GLENMARK |
| Adare Pharma Solutions |
AI Analysis | Feedback
Lisa Conte, President, Chief Executive Officer, and Member of the Board of Directors
Lisa Conte has a strong background in the pharmaceutical industry, having served as President, Chief Executive Officer, and Member of the Board of Directors at Jaguar Health since 2014. She was also the Interim Chief Executive Officer and Director at Napo Pharmaceuticals, Inc. starting in 2001. Notably, Ms. Conte founded Shaman Pharmaceuticals, Inc. in 1989, where she was President and CEO until 2001. In July 2017, Napo Pharmaceuticals merged with Jaguar Animal Health (both founded by Ms. Conte) to form Jaguar Health. She has over 30 years of experience pioneering plant-based prescription medicine investigation and development.
Carol Lizak, Chief Financial Officer
Carol Lizak was promoted to Chief Financial Officer of Jaguar Health in April 2021, having joined the company in May 2019 as Senior Vice President of Finance and Chief Accounting Officer. She possesses over 20 years of experience in corporate controllership and financial planning & analysis under U.S. GAAP & IFRS. Prior to her tenure at Jaguar Health, Ms. Lizak held positions as senior director and corporate controller of Zosano Pharma Corporation, controller of Quantum Secure, Inc., and executive director, corporate controller of Alexza Pharmaceuticals, Inc. She also spent nine years as corporate controller of a subsidiary of HID Global Corporation.
Ian H. Wendt, Chief Commercial Officer
Ian H. Wendt has over three decades of experience in the biotechnology and pharmaceutical sectors. Before joining Jaguar Health, he held various field leadership and marketing roles at Gilead Sciences, focusing on HIV and hepatitis C therapeutic areas. His responsibilities at Gilead included leading strategy and tactical development for a national team and efforts to increase hepatitis C virus screening. Prior to Gilead, Mr. Wendt worked at Boehringer Ingelheim, where he led HIV and oncology sales teams, and at Roxane Laboratories, where he headed commercial operations.
Pravin Chaturvedi, Chief Scientific Officer & Chair of Scientific Advisory Board
Pravin Chaturvedi serves as the Chief Scientific Officer and Chair of the Scientific Advisory Board at Jaguar Health. He has been in a chief technical, scientific, or R&D officer role since January 2022.
Jonathan Wolin, Chief of Staff, Chief Compliance Officer & General Counsel
Jonathan Wolin holds the titles of Chief of Staff, Chief Compliance Officer, and General Counsel at Jaguar Health. He has been the Compliance Officer and General Counsel since January 2018, and Human Resources Officer since April 2019.
AI Analysis | Feedback
The key risks to Jaguar Health (JAGX) are primarily centered around its financial viability, regulatory and clinical trial success, and its heavy reliance on a single product.
- Financial Instability and Going Concern Risk: Jaguar Health faces significant financial challenges, including a high probability of bankruptcy, substantial operating losses, and a concerning cash burn rate. The company reported widened operating losses and a significant net loss per share in Q2 2025. Its debt-to-equity ratio is high, and cash balances have been insufficient to cover operational needs for an extended period, leading to an explicit disclosure by management regarding "substantial doubt about going concern" without additional financing or partnerships. The company's Altman Z-Score places it in the distress zone, indicating a high risk of bankruptcy within the next two years.
- Regulatory and Clinical Trial Risks: The company's future growth and financial stability are heavily dependent on the successful outcomes of clinical trials and subsequent regulatory approvals for its drug candidates. While Jaguar Health is pursuing orphan drug designations and expedited approval pathways for crofelemer in conditions like metastatic breast cancer with chemotherapy-induced diarrhea (CTD), short bowel syndrome-intestinal failure (SBS-IF), and microvillus inclusion disease (MVID), these processes are inherently uncertain. A recent Phase 3 clinical trial for crofelemer in preventing diarrhea in adult cancer patients with solid tumors failed to meet its primary endpoint, leading to a significant drop in stock price. The success of these regulatory efforts and trials is crucial for unlocking potential market opportunities.
- Reliance on a Single Product and Limited Revenue Growth: Jaguar Health's revenue generation is heavily concentrated on its flagship product, Mytesi. While Mytesi sales have shown some stability, the company's overall revenue growth has been modest or declining, and it continues to be unprofitable. This heavy reliance on a single product exposes Jaguar Health to significant revenue volatility and intensifies the impact of any clinical setbacks, regulatory hurdles, or market competition related to Mytesi or its potential new indications.
AI Analysis | Feedback
null
AI Analysis | Feedback
Jaguar Health (JAGX) focuses on developing and commercializing plant-based prescription and non-prescription products for both human and animal gastrointestinal distress. The addressable markets for their main products and services are as follows:
- Mytesi (crofelemer) for HIV-related diarrhea: The estimated potential market in the U.S. is approximately $100 million in gross annual sales.
- Crofelemer for Chemotherapy-Induced Diarrhea (CID) in humans: Market size information for Mytesi for CID is available for seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Specific aggregated market values for these regions were not provided in the search results.
- Canalevia-CA1 (crofelemer) for Chemotherapy-Induced Diarrhea (CID) in dogs: In the U.S., between 600,000 and 1.5 million dogs receive chemotherapy annually, with 40% potentially experiencing diarrhea. The FDA estimates that fewer than 70,000 dogs in the U.S. suffer from CID annually, which qualifies it as a minor use in a major species. More recently, the "small number" threshold for CID in dogs for Minor Use in a Major Species (MUMS) designation in the U.S. is stated as 80,000.
- Canalevia (crofelemer) for general non-infectious diarrhea in dogs: Approximately 11 million dogs in the U.S. suffer from general diarrhea annually. U.S. veterinarians see about six million annual cases of acute and chronic diarrhea in dogs. The European market for dogs is estimated at approximately 140 million.
- Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Microvillus Inclusion Disease (MVID): SBS affects an estimated 10,000 to 20,000 people in the U.S., with a similar population size in Europe.
- Equilevia (equine gut health product): The global equine healthcare market size was estimated at USD 3.22 billion in 2024 and is projected to reach USD 6.41 billion by 2033, with a compound annual growth rate (CAGR) of 8.20% from 2025 to 2033. Another estimate places the global equine health market at USD 2.08 billion in 2024, growing to USD 3.53 billion by 2032 with a CAGR of 6.9% during the forecast period. The pharmaceuticals segment constituted the largest share of the equine healthcare market in 2024.
- Gelclair (oral mucositis): No specific addressable market size for oral mucositis or Gelclair was identified in the provided search results.
AI Analysis | Feedback
Jaguar Health (JAGX) is positioned for future revenue growth over the next 2-3 years, driven by several strategic initiatives and pipeline advancements centered around its key compound, crofelemer. The expected drivers include expansion into new therapeutic indications for crofelemer in human health, growth and expanded indications in animal health, penetration of European markets, and increased sales of its currently approved human drug through strategic partnerships.
- Expansion of Crofelemer (Mytesi) Indications in Human Health: A significant driver of future revenue growth for Jaguar Health is the ongoing development and anticipated regulatory approvals for new indications for crofelemer. The company is actively pursuing the expansion of Mytesi for chemotherapy-related diarrhea (CTD), particularly in metastatic breast cancer patients, with potential market availability projected by 2026. Additionally, crofelemer is in advanced stages for the ultra-rare diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF). Initial proof-of-concept data has shown promising results in reducing the need for parenteral nutrition in these patient populations, and Jaguar Health aims for expedited FDA approval for MVID by 2026, with SBS-IF approval expected to follow.
- Growth and Expanded Indications for Canalevia-CA1 in Animal Health: Jaguar Health's animal health segment, under the Jaguar Animal Health tradename, is expected to contribute to revenue growth. Canalevia-CA1 (crofelemer) received conditional approval in December 2021 for chemotherapy-induced diarrhea in dogs, and the company continues its launch, education, and promotional activities. Furthermore, discussions are underway to expand Canalevia-CA1's indication to treat general diarrhea in dogs, which would significantly broaden its market potential.
- European Market Penetration for Crofelemer via Napo Therapeutics: The establishment of Napo Therapeutics in Milan, Italy, in 2021 signals Jaguar Health's strategy to expand crofelemer access in Europe. This subsidiary is focused on bringing crofelemer to European markets, specifically for orphan and rare diseases such as MVID and SBS-IF, with proof-of-concept study results anticipated throughout 2025 and planned Phase 2 trials. Successful market entry and adoption in Europe would represent a new geographical revenue stream.
- Increased Sales of Existing Mytesi Indication and Strategic Partnerships: Continued growth in sales of Mytesi for its currently approved indication—symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy—remains a foundational revenue driver. Jaguar Health has engaged in co-promotion agreements to extend the reach of Mytesi into the gastrointestinal medical community. Moreover, the company is actively seeking corporate partnerships and business development deals to secure non-dilutive funding and broaden market access for its products, particularly in the rare disease space, which can accelerate overall revenue growth by facilitating wider commercialization.
AI Analysis | Feedback
Share Issuance
- In April 2025, Jaguar Health completed a private placement, securing approximately $3.448 million through the issuance of convertible promissory notes and unregistered warrants.
- In May 2025, the company announced a registered direct offering and concurrent private placement expected to raise approximately $1.5 million from the sale of 246,306 shares of common stock and the issuance of unregistered warrants for up to 492,612 additional shares.
- Jaguar Health has utilized an At-the-Market (ATM) financing program, raising approximately $30.8 million in 2024 through this method, and upsizing the program by $15.3 million in April 2021 for potential future financing needs.
Inbound Investments
- In February 2023, Jaguar Health's subsidiary, Napo Therapeutics S.p.A. (in which Jaguar holds about 73.5% ownership), successfully closed an initial private placement financing round at a fully diluted valuation of approximately €55 million, with plans to raise up to €7 million to support clinical development.
- Jaguar Health received a $250,000 grant from the FDA in September 2025 for research related to chemotherapy-induced diarrhea in dogs.
Capital Expenditures
- Jaguar Health's historical capital expenditures were minimal, reported as $0 million in 2020, $0 million in 2021, $2 million in 2022, $0 million in 2023, and $0 million in 2024.
- The company's projected capital expenditures are $0 million for 2025 and $1 million annually from 2026 to 2029.
- Proceeds from a May 2025 direct offering were earmarked for general corporate purposes, including capital expenditures.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Jaguar Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.70 |
| Mkt Cap | 58.9 |
| Rev LTM | 5,868 |
| Op Inc LTM | -62 |
| FCF LTM | 1,655 |
| FCF 3Y Avg | 1,017 |
| CFO LTM | 1,846 |
| CFO 3Y Avg | 1,195 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.4% |
| Rev Chg 3Y Avg | 6.8% |
| Rev Chg Q | 5.1% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | -139.6% |
| Op Mgn 3Y Avg | -132.1% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | -94.6% |
| CFO/Rev 3Y Avg | -121.5% |
| FCF/Rev LTM | -97.1% |
| FCF/Rev 3Y Avg | -124.0% |
Price Behavior
Price Behavior
| Market Price | $0.81 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/13/2015 | |
| Distance from 52W High | -96.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.21 | $2.98 |
| DMA Trend | down | down |
| Distance from DMA | -33.3% | -72.8% |
| 3M | 1YR | |
| Volatility | 226.2% | 2,532.5% |
| Downside Capture | 454.12 | 424.84 |
| Upside Capture | -54.11 | 38.13 |
| Correlation (SPY) | 23.0% | 10.2% |
JAGX Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.64 | 2.45 | 2.87 | 2.60 | 12.96 | 7.53 |
| Up Beta | -0.86 | -1.04 | 0.49 | 2.12 | 20.70 | 14.20 |
| Down Beta | 4.00 | 3.21 | 3.04 | 3.10 | 1.05 | 1.65 |
| Up Capture | 162% | -33% | 56% | 57% | 30% | -2% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 9 | 18 | 26 | 54 | 100 | 295 |
| Down Capture | 781% | 442% | 395% | 290% | 170% | 113% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 13 | 23 | 35 | 66 | 143 | 436 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JAGX | |
|---|---|---|---|---|
| JAGX | -96.2% | 2,532.5% | 0.87 | - |
| Sector ETF (XLV) | 14.5% | 17.4% | 0.62 | 4.7% |
| Equity (SPY) | 15.8% | 19.3% | 0.63 | 10.1% |
| Gold (GLD) | 79.5% | 20.4% | 2.78 | -3.6% |
| Commodities (DBC) | 5.7% | 15.3% | 0.16 | 1.9% |
| Real Estate (VNQ) | 5.8% | 16.7% | 0.17 | 9.9% |
| Bitcoin (BTCUSD) | -14.7% | 39.8% | -0.31 | 11.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JAGX | |
|---|---|---|---|---|
| JAGX | -94.2% | 1,134.8% | 0.25 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 3.3% |
| Equity (SPY) | 14.0% | 17.1% | 0.66 | 6.7% |
| Gold (GLD) | 20.8% | 15.7% | 1.07 | -1.4% |
| Commodities (DBC) | 11.4% | 18.7% | 0.49 | 0.9% |
| Real Estate (VNQ) | 5.7% | 18.8% | 0.21 | 5.3% |
| Bitcoin (BTCUSD) | 19.0% | 58.0% | 0.53 | 4.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JAGX | |
|---|---|---|---|---|
| JAGX | -87.9% | 814.6% | 0.18 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.53 | 2.2% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 4.8% |
| Gold (GLD) | 15.7% | 14.9% | 0.87 | -0.7% |
| Commodities (DBC) | 8.2% | 17.6% | 0.38 | 1.3% |
| Real Estate (VNQ) | 5.8% | 20.8% | 0.25 | 3.4% |
| Bitcoin (BTCUSD) | 70.3% | 66.7% | 1.09 | 2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/15/2025 | 6.9% | -17.6% | -37.3% |
| 11/13/2024 | -9.4% | -11.1% | -10.5% |
| 8/13/2024 | -10.8% | 3.3% | -5.8% |
| 8/14/2023 | -6.5% | -12.6% | -40.7% |
| 3/27/2023 | -8.0% | -44.5% | -57.8% |
| 11/14/2022 | -6.3% | -13.3% | -19.9% |
| 3/11/2022 | -3.3% | 52.8% | 41.1% |
| 11/18/2021 | 4.1% | -4.8% | -20.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 3 | 4 | 3 |
| # Negative | 9 | 8 | 9 |
| Median Positive | 6.9% | 5.6% | 41.1% |
| Median Negative | -6.5% | -13.0% | -20.7% |
| Max Positive | 10.0% | 52.8% | 96.7% |
| Max Negative | -13.5% | -44.5% | -57.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/14/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/15/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/31/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/13/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/13/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/14/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 04/01/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/14/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/14/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/15/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/24/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/14/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/22/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/10/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/11/2022 | 10-K (12/31/2021) |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.